U.S. Professional Services Stock News

If you are wondering whether Plains GP Holdings is attractively priced at its current level, this article walks through what the numbers are really saying about the stock. The share price recently closed at US$19.83, with returns of 2.2% over the last 7 days, 6.0% over the last 30 days, 2.2% year to date, 7.2% over 1 year, 92.5% over 3 years and 168.8% over 5 years, which may influence how you think about potential reward and risk. Recent price moves sit against a backdrop of ongoing...

If you are wondering whether Colgate-Palmolive at around US$81.48 is a fair deal or a stretch, you are in the right place to unpack what that price might really be offering you. The stock has returned 4.9% over the last week and 4.8% over the last month, while the 1 year return sits at a 3.4% decline and the 3 and 5 year returns are 12.4% and 11.9% respectively. Recent coverage around Colgate-Palmolive has focused on its position as a global consumer staples brand and how investors treat it...

In early January 2026, Roblox began rolling out mandatory, privacy-focused facial age verification for chat worldwide, restricting communication between adults and younger users while aiming to strengthen safety and regulatory compliance across its platform. This safety push, arriving alongside diverging analyst views on engagement trends and profitability, raises important questions about how stricter controls might affect user behavior and Roblox’s broader business model. Next, we’ll...

In recent days, several major research firms, including Wells Fargo, Mizuho, and Evercore ISI, reiterated positive views on Hubbell, reinforcing confidence in its operations and earnings outlook. This cluster of upbeat opinions comes as Hubbell posts strong multi‑year earnings growth alongside a valuation that suggests investors are already paying a premium for its shares. We’ll now examine how this wave of upbeat analyst sentiment may influence Hubbell’s existing investment narrative and...

PJT Partners (PJT) has drawn investor attention after recent gains over the past week, with the stock closing at US$179.53. That move comes alongside recent revenue of US$1,657.789 million. See our latest analysis for PJT Partners. The latest weekly gain fits into a steadier picture, with a 90 day share price return of 4.99% and a 1 year total shareholder return of 16.81% pointing to building momentum, supported by a very large 3 year total shareholder return of 132.94%. If PJT Partners has...

If you are wondering whether Ondas Holdings at US$13.69 still offers value after its run, you are not alone. The stock’s recent history gives plenty to think about. The share price moves have been sharp, with returns of 24.2% over the last week, 64.4% over the last month and a very large gain over the last year, which naturally raises questions about risk and sustainability. These moves have been playing out against a backdrop of ongoing interest in the company’s technology and growth story,...

Earlier this week, Broadcom Inc. announced its next-generation BCM4918 accelerated processing unit and new dual-band Wi‑Fi 8 chips, aiming to unify high-performance computing, networking, AI acceleration, and energy-efficient wireless connectivity for AI-enabled homes. At the same time, Broadcom completed several fixed-rate senior unsecured note issuances totaling about US$4.49 billion, potentially giving it added financial flexibility to support expanding AI chip demand and product...

Why Macerich’s mall reinvention is back on investors’ radar Macerich (MAC) is back in focus as investors weigh its push to convert traditional malls into mixed-use centers, alongside ongoing questions around high debt, refinancing needs, and how consumers might respond to these redeveloped properties. See our latest analysis for Macerich. While the share price has eased slightly in the very short term, Macerich’s 90 day share price return of 11.1% and 3 year total shareholder return of 67%...

T. Rowe Price Group recently drew renewed attention as a steady, dividend-focused asset manager, while analysts projected its fiscal 2025 fourth-quarter diluted earnings at US$2.47 per share, reflecting double-digit profit growth compared with the prior year. At the same time, the firm has been expanding its footprint through initiatives such as backing advanced manufacturing start-up Hadrian and engaging in Venezuelan debt restructuring talks, underscoring its reach across both public and...

In recent days, Century Aluminum has experienced sharp volatility as global metals markets react to swings in aluminum prices, energy costs, and evolving U.S. industrial policies. Unusually heavy and divided options activity from large investors highlights how shifting institutional sentiment is amplifying the company’s sensitivity to these broader market forces. We’ll now examine how this heightened institutional options activity and macro-driven volatility could reshape Century...

In recent days, Freedom Capital Markets initiated coverage of NioCorp Developments Ltd., highlighting U.S. government support for rare-earth mining and the company’s high-quality deposits, production capabilities, and offtake contracts. This combination of policy backing and resource quality helps frame NioCorp as a potential beneficiary of efforts to strengthen domestic critical minerals supply chains. Next, we’ll examine how this new analyst coverage and its focus on U.S. government...

If you are wondering whether Okta's share price reflects its true worth today, you are not alone. This article will help you frame that question clearly before you make any decisions. Okta shares last closed at US$92.23, with returns of 10.3% over the past week, 2.7% over the past month, 10.3% year to date and 9.3% over the last year, while the 3 year return stands at 32.2% and the 5 year return at a 63.5% decline. Recent headlines around Okta have focused on its role in identity and access...

Exelixis (EXEL) is back in focus after reporting strong phase 3 data for zanzalintinib in metastatic colorectal cancer, alongside launching the Natera partnership for the planned STELLAR-316 pivotal trial in earlier stage disease. See our latest analysis for Exelixis. The recent phase 3 readout for zanzalintinib and the planned STELLAR-316 trial come after a strong run in the shares, with a 90 day share price return of 15.44% and a 1 year total shareholder return of 22.27%. The 3 year total...

Commercial Metals (CMC) has just posted its Q1 2026 results, with Q4 2025 revenue at US$2.1 billion and basic EPS of US$1.36, setting the tone for how the new fiscal year is starting to shape up. Over recent quarters the company has seen revenue move from US$2.0 billion in Q3 2025 to US$2.1 billion in Q4 2025, while basic EPS shifted from US$0.74 to US$1.36, giving investors fresh numbers to weigh against a mixed earnings backdrop. With trailing 12 month profit margins under pressure and a...

AnaptysBio recently filed a partial motion to dismiss Tesaro’s anticipatory breach of contract claim in Delaware Chancery Court, while a trial covering all remaining issues in their collaboration dispute is scheduled for July 14–17, 2026. The company has also announced plans to separate its biopharma operations from its sizeable royalty assets by the end of 2026, signaling a potential shift in how investors assess its underlying business drivers. We will now examine how AnaptysBio’s plan to...

Why SIGA is back on investors’ radar SIGA Technologies (SIGA) is drawing fresh attention after recent coverage highlighted its TPOXX smallpox antiviral, consistent profitability, and solid balance sheet, even as major new contract or regulatory announcements remain quiet. See our latest analysis for SIGA Technologies. At a share price of US$6.77, SIGA has seen a 10.8% 7 day share price return and an 8.3% 30 day share price return, while its 1 year total shareholder return of 19.1% points to...

In early January 2026, Permian Resources Corporation filed new universal shelf registrations covering Class A common stock, preferred stock and warrants, while also closing several prior employee stock ownership plan (ESOP) related shelves and withdrawing a 2024 omnibus shelf. Alongside these filings, the company completed a corporate reorganization and saw multiple senior executives sell shares, some to cover tax obligations from vested performance stock, reshaping its capital structure and...

Corewell Health and Quest Diagnostics recently completed their Diagnostic Lab of Michigan joint venture, giving Quest 51% ownership and extending its Collaborative Lab Solutions across 21 Corewell hospitals, with a new facility planned for early 2027. This majority-owned partnership meaningfully deepens Quest’s hospital footprint in Michigan, potentially reinforcing its role as an outsourced lab partner for large health systems. We’ll now examine how this expanded Corewell partnership, and...

In recent days, Dash Social announced a partnership making it an Official Snapchat Partner, allowing brands to publish directly to Snapchat and access real-time, API-sourced analytics, while Snap also reported quarterly results that exceeded analyst expectations and issued strong guidance for the following quarter. Together with the appointment of technology executive Matthew McRae to Snap’s board and CEO Evan Spiegel’s pre-planned share sale of about US$10,000,000, these developments...

In recent years, H.B. Fuller’s return on capital employed has risen to 8.3%, while the capital base expanded by 27%, highlighting stronger operational efficiency and reinvestment. This combination of higher returns and greater capital employed suggests the company is finding more productive ways to reinvest internally, which may not yet be fully appreciated in the market. We’ll now explore how H.B. Fuller’s improving return on capital employed reshapes its existing investment narrative and...

On January 7, 2026, Jamie Reynoso, CEO of Medicare Advantage at Clover Health Investments (CLOV), sold 2,102 shares, adding to a wider pattern of insider selling that some investors may want to watch. See our latest analysis for Clover Health Investments. Clover Health Investments’ share price, which last closed at US$2.53, has seen a 7.7% 7 day share price return and a 5.0% year to date share price return. Its 1 year total shareholder return reflects a 30.5% loss, suggesting recent momentum...

If you are wondering whether Rocket Lab's current share price reflects its true worth, this article walks through what the numbers actually say about value. Rocket Lab's share price recently closed at US$83.08, with returns of 19.1% over 7 days, 55.5% over 30 days, 9.3% year to date and 203.7% over 1 year, and a very large return over 3 and 5 years. These sharp moves have kept Rocket Lab on many investors' watchlists, as the stock reacts to ongoing developments around its business and...

If you are wondering whether Centene's current share price reflects its underlying value, you are not alone. This article will help you frame that question clearly. Centene's stock recently closed at US$46.92, with returns of 14.0% over 7 days, 23.2% over 30 days, 12.3% year to date, but with a 25.7% decline over 1 year, a 40.0% decline over 3 years, and a 27.8% decline over 5 years. These mixed return figures have put renewed attention on how the market is currently assessing managed care...

If you are wondering whether Halliburton’s current share price lines up with its underlying worth, this breakdown will help you see how the numbers stack up. Halliburton shares last closed at US$32.63, with returns of 10.2% over the past week, 12.4% over the last 30 days, 10.2% year to date and 24.6% over the past year, while the 3 year return is an 18.1% decline and the 5 year return is 72.2%. Recent news flow around Halliburton has continued to focus on its role as a major U.S. oilfield...